Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Why Ionis Pharmaceuticals Is Tumbling 10% Today

What happened

After highly regarded investment firm Goldman Sachs cut its rating on the company, Ionis Pharmaceuticals (NASDAQ: IONS  )  shares dropped by more than 10% at 1:45 p.m. EST today.

So what

Until today, it's been a good time to be an Ionis Pharmaceuticals investor. In December, the company's collaboration partner Biogen won Food and Drug Administration approval for Spinraza, a potential billion-dollar blockbuster therapy for spinal muscular atrophy, and late last month, the company reported better-than-expected financial results that included a goal of achieving pro forma profitability this year.

Scientists work together developing new drugs in a lab.

IMAGE SOURCE: GETTY IMAGES.

Despite that headway, Goldman Sachs isn't impressed. According to Bloomberg, analyst Salveen Richter is telling institutional clients that Ionis Pharmaceuticals' shares could topple 45%.

Richter's price target of $25 comes after Ionis Pharmaceuticals reported phase 3 results for volanesorsen earlier this month. Volanesorsen is being developed for use in familial chylomicronemia syndrome, and trial results were good enough for management to say they plan to pursue FDA approval. Richter's skeptical, however, that volanesorsen will be a winner.

Richter also tossed cold water on the potential commercial opportunity for IONS-TTrx, a drug being developed by GlaxoSmithKline that should read out phase 3 results in Q2. 

Now what

Undeniably, this is an important year for Ionis Pharmaceuticals. If Biogen can successfully market Spinraza, then royalties in the teens, plus licensing and royalty revenue on other drugs in its pipeline, could allow Ionis Pharmaceuticals to turn the corner to profitability. 

The volanesorsen data could result in an FDA application for approval this year, and if GlaxoSmithKline reports positive results for TTrx, then a filing for approval could be on deck this year for that drug, too. The company also hopes to add up to five new drug candidates to its research and development pipeline this year. 

Of course, there's no guarantee that all of these things are going to go Ionis Pharmaceuticals' way. Spinraza is a pricey medicine, and its launch trajectory could be slowed by insurers who want to delay its use. Furthermore, volanesorsen could get rejected by regulators -- and the trial for TTrx could be a bust. Those are real risks that investors shouldn't ignore.

Nevertheless, few biotech stocks have the pipeline depth and breadth of Ionis Pharmaceuticals or anywhere near the same number of deep-pocketed collaboration partners. Given royalty revenue is high margin and the maturing pipeline offers opportunities for additional income in 2018 and beyond, investors might be best served remaining focused on the long term, rather than reacting to individual analyst reports. 

10 stocks we like better than Ionis Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Ionis Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4008001, ~/Articles/ArticleHandler.aspx, 3/25/2017 1:43:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
Change down DOW 20596.7 -59.9 -0.3%
Change down S&P 500 2344.0 -2.0 -0.1%
Change up NASD 5828.7 11.0 0.2%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/24/2017 4:00 PM
IONS $38.98 Up +1.05 +2.77%
Ionis Pharmaceutic… CAPS Rating: *****

Advertisement